UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1, 97.9) ...
Tecentriq SC, launched in India by the pharma giant Roche, is subcutaneous. This means it is injected directly under the skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results